25 completed, 5 terminated, 1 unknown. 19 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 13, Terminated 5, Unknown 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 3 |
Follow ThromboGenics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) Eplerenone - Vitreomacular Traction, Subretinal Edema | Phase 2 | Terminated | Wagner Macula & Retina Center | 2 | 2019-10-04 | 2021-01-08 |
| A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) THR-317 8mg - Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia | Phase 2 | Completed | ThromboGenics | 8 | 2018-09-18 | 2020-09-02 |
| A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME) THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3 - Diabetes Mellitus, Diabetic Retinopathy | Phase 1 | Completed | ThromboGenics | 12 | 2018-09-17 | 2020-01-22 |
| A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME) THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3 - Diabetes Mellitus, Diabetic Retinopathy | Phase 1 | Completed | ThromboGenics | 12 | 2018-05-18 | 2019-06-13 |
| A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME) Anti-PlGF recombinant monoclonal antibody, 4mg dose, Anti-PlGF recombinant monoclonal antibody, 8mg dose - Diabetic Retinopathy, Macular Edema | Phase 2 | Completed | ThromboGenics | 49 | 2016-12-22 | 2018-04-17 |
| A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection - Diabetic Retinopathy, Posterior Vitreous Detachment | Phase 2 | Terminated | ThromboGenics | 48 | 2015-12-01 | 2020-12-16 |
| A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Symptomatic Vitreomacular Adhesion (VMA) | Completed | ThromboGenics | 134 | 2014-08-01 | 2015-07-09 | |
| Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older Vitreomacular Adhesion | Completed | Nova Southeastern University | 1584 | 2014-05-01 | 2018-03-29 | |
| Ocriplasmin Research to Better Inform Treatment (ORBIT) Symptomatic Vitreomacular Adhesion | Completed | ThromboGenics | 540 | 2014-05-01 | 2016-06-21 | |
| Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Ocriplasmin, Sham injection - Vitreomacular Adhesion Including Macular Hole | Phase 3 | Completed | ThromboGenics | 220 | 2011-10-01 | 2016-03-14 |
| Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies ocriplasmin, placebo - Symptomatic Vitreomacular Adhesion | Completed | ThromboGenics | 24 | 2011-05-01 | 2017-01-13 | |
| Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery TB-402, Rivaroxaban - Prophylaxis of Venous Thromboembolic Events | Phase 2 | Completed | ThromboGenics | 632 | 2011-04-01 | 2012-08-23 |
| The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) ocriplasmin - Vitrectomy | Phase 2 | Completed | ThromboGenics | 38 | 2010-07-01 | 2014-12-17 |
| Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy Ocriplasmin, Placebo - Vitrectomy | Phase 2 | Completed | ThromboGenics | 24 | 2010-02-01 | 2014-12-17 |
| Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion Ocriplasmin, Sham injection - Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion | Phase 2 | Completed | ThromboGenics | 100 | 2010-01-01 | 2014-12-17 |
| Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion Microplasmin - Focal Vitreomacular Adhesion | Phase 2 | Completed | ThromboGenics | 17 | 2010-01-01 | 2014-04-07 |
| Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration Microplasmin, Placebo control - Macular Degeneration | Phase 2 | Unknown | University of California, Los Angeles | 30 | 2009-10-01 | 2011-09-27 |
| Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery TB-402, Enoxaparin - Total Knee Replacement Surgery | Phase 2 | Completed | ThromboGenics | 316 | 2008-12-01 | 2014-04-07 |
| Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. Ocriplasmin 125µg, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
| Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. 125 µg Ocriplasmin, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
Showing 20 of 31. Sign in to see all of them.
Diabetic Retinopathy (5) · Diabetes Mellitus (2) · Macular Degeneration (2) · Stroke (2) · Vitreous Detachment (2) · Arterial Occlusive Diseases (1) · Disease Progression (1) · Eye Diseases (1) · Idiopathic Juxtafoveal Retinal Telangiectasia (1) · Ischemic Stroke (1) · Macular Edema (1) · Retinal Perforations (1) · Retinal Telangiectasis (1) · Thromboembolism (1) · Venous Thrombosis (1)
microplasmin (18) · TB 402 (5) · salicylhydroxamic acid (4) · Enoxaparin (1) · Eplerenone (1) · Rivaroxaban (1) · TB-403 (1)
United States (15) · Belgium (11) · Germany (7) · Netherlands (4) · United Kingdom (4) · Czechia (3) · Denmark (3) · France (3) · Hungary (3) · Italy (3) · Poland (3) · Spain (3) · Austria (2) · Bulgaria (2) · Israel (2)
Thomas J Jensen, MD, PhD (2) · Gerard O'Sullivan, MD (1) · Gerhard Hamann, Prof. Dr (1) · Julie A Rodman, OD, MS, FAAO (1) · Peter Verhamme, MD, PhD (1) · Steven D Schwartz, M.D. (1) · Thomas J Jensen, M.D. (1) · Vincent Thijs, MD PhD (1)
PMID 22879421, PMID 22894573, PMID 23033391, PMID 26068086, PMID 20637972, PMID 23982845, PMID 30350717, PMID 30935657, PMID 34250257
2015 (1), 2016 (1), 2017 (1)